10.20
-0.66 (-6.08%)
| 前收盘价格 | 10.86 |
| 收盘价格 | 10.85 |
| 成交量 | 2,366,201 |
| 平均成交量 (3个月) | 2,304,195 |
| 市值 | 1,859,667,072 |
| 预期市盈率 (P/E Forward) | 36.90 |
| 价格/销量 (P/S) | 4.67 |
| 股市价格/股市净资产 (P/B) | 107.68 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业毛利率 | -20.25% |
| 营业利益率 (TTM) | -5.14% |
| 稀释每股收益 (EPS TTM) | -0.290 |
| 季度收入增长率 (YOY) | 47.90% |
| 流动比率 (MRQ) | 1.72 |
| 营业现金流 (OCF TTM) | -26.71 M |
| 杠杆自由现金流 (LFCF TTM) | -5.90 M |
| 资产报酬率 (ROA TTM) | -3.14% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Xeris Biopharma Holdings, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 4.0 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | 1.50 |
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.19% |
| 机构持股比例 | 54.46% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合